As we step into 2025, we at MyCural Therapeutics want to take a moment to express our gratitude to everyone who has been part of our journey in 2024—our dedicated team, supportive partners, investors, and the wider scientific and business communities. Last year was transformative for us, marked by innovation, growth, and recognition. Every achievement brings us closer to our mission: transforming the future of cancer treatment.
Milestones and Achievements in 2024
Funding Success
In 2024, we successfully oversubscribed our latest investment round, bringing new investors on board. Additionally, we secured a grant from Vinnova, further fueling our mission to develop MYC-targeted therapies for patients with high-risk tumors.
We are deeply grateful to our investors and supporters for believing in our vision and contributing to this pivotal step. Your trust empowers us to push the boundaries of cancer research and development.
Growing Our Team
This year, we celebrated a major milestone: MyCural Therapeutics has grown into a team of 20 exceptional individuals!
From scientists to business developers, drug development experts, research engineers specializing in biology and biophysics, medicinal chemists, and communication and branding professionals, our multidisciplinary team is united by one mission: transforming cancer treatment.
Every team member’s unique expertise and passion drive our progress. Together, we’re making significant advancements in targeting the MYC protein and developing innovative cancer therapies. To the amazing people who make MyCural what it is today—your dedication inspires us every day!
Nordic Star 2024 Award
We are honored to have received the Nordic Star 2024 Award at Nordic Life Science Days, being recognized as The Most Investable Company. This prestigious acknowledgment highlights not only the significant commercial potential of our work but also the critical clinical need we are addressing with our innovative MYC-targeted therapies.
The jury noted, “The winning company is working on a well-validated clinical unmet need that also harbors significant commercial potential. As an investor, we are always on the look for innovative approaches with platform potential, and that is what we see in MyCural.”
This recognition is a testament to the dedication of our team and the transformative potential of our work. It inspires us to continue driving innovation and delivering on our mission to revolutionize cancer therapy.
Proudest Moments of 2024
- US Patent Granted: A major step in protecting our innovative MYC-targeted therapies.
- UIC Accelerator Program: Accepted into the program to accelerate our journey forward.
- Media Features: Showcased in Dagens Industri and Dagens Nyheter, highlighting our advancements and strengthening our position as leaders in cancer research innovation.
- NOME Selection: Chosen as one of six companies (out of over 200) to pitch at the Nordic Mentor Network for Entrepreneurship.
A Year of Impactful Events
2024 was filled with meaningful connections and opportunities to share our mission with the world. We had the honor of participating in several incredible events and conferences, including:
- NOME Startup Competition
- BIO-Europe Partner Conference
- MyCural Day Research Workshops
- Uppsala Innovation Day Showcasing
- NLS Days Partner Conference
- Meet & Match Biotech Edition
- Biotech Hanse Forum
- Swiss Nordic Bio 2024
These platforms allowed us to engage with industry leaders, partners, investors, and collaborators who share our passion for advancing cancer research. Each event has been a stepping stone toward making our MYC-targeted therapies a reality. To all the organizers, attendees, and partners we met along the way—thank you for making this year so impactful. We look forward to continuing this journey together in 2025.
Looking Ahead to 2025
As we welcome 2025, we’re excited to build on this momentum. With ambitious goals and groundbreaking milestones ahead, we remain committed to transforming cancer research and innovation. Together, let’s make this year even more impactful.
